Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
- PMID: 33069969
- DOI: 10.1016/j.biopha.2020.110862
Ziyuglycoside II alleviates cyclophosphamide-induced leukopenia in mice via regulation of HSPC proliferation and differentiation
Abstract
Ziyuglycoside II (ZGS II) is a major bioactive ingredient of Sanguisorbae officinalis L., which has been widely used for managing myelosuppression or leukopenia induced by chemotherapy or radiotherapy. In the current study, we investigated the pro-hematopoietic effects and underlying mechanisms of ZGS II in cyclophosphamide-induced leukopenia in mice. The results showed that ZGS II significantly increased the number of total white blood cells and neutrophils in the peripheral blood. Flow cytometry analysis also showed a significant increase in the number of nucleated cells and hematopoietic stem and progenitor cells (HSPCs) including ST-HSCs, MPPs, and GMPs, and enhanced HSPC proliferation in ZGS II treated mice. The RNA-sequencing analysis demonstrated that ZGS II effectively regulated cell differentiation, immune system processes, and hematopoietic system-related pathways related to extracellular matrix (ECM)-receptor interaction, focal adhesion, hematopoietic cell lineage, cytokine-cytokine receptor interaction, the NOD-like receptor signaling pathway, and the osteoclast differentiation pathway. Moreover, ZGS II treatment altered the differentially expressed genes (DEGs) with known functions in HSPC differentiation and mobilization (Cxcl12, Col1a2, and Sparc) and the surface markers of neutrophilic precursors or neutrophils (Ngp and CD177). Collectively, these data suggest that ZGS II protected against chemotherapy-induced leukopenia by regulating HSPC proliferation and differentiation.
Keywords: Hematopoietic stem and progenitor cells; Leukopenia; Proliferation; RNA-seq; Ziyuglycoside II.
Copyright © 2020. Published by Elsevier Masson SAS.
Similar articles
-
Ziyuglycoside II, a triterpene glycoside compound in Sanguisorbae officinalis l. extract, suppresses metastasis in osteosarcoma via CBX4-mediated Wnt/β-catenin signal pathway.Phytomedicine. 2024 Sep;132:155716. doi: 10.1016/j.phymed.2024.155716. Epub 2024 May 9. Phytomedicine. 2024. PMID: 38924929
-
Sanguisorba parviflora (Maxim) Takeda alleviates cyclophosphamide-induced leukopenia via regulating the hematopoietic cell-specific protein 1-associated protein X-1 gene.J Clin Pharm Ther. 2021 Oct;46(5):1334-1342. doi: 10.1111/jcpt.13450. Epub 2021 Jun 1. J Clin Pharm Ther. 2021. PMID: 34075619
-
Response of Hematopoietic Stem and Progenitor Cells to Reserpine in C57Bl/6 Mice.Bull Exp Biol Med. 2016 Feb;160(4):439-43. doi: 10.1007/s10517-016-3191-y. Epub 2016 Feb 23. Bull Exp Biol Med. 2016. PMID: 26902356
-
The pro-Inflammatory cytokines effects on mobilization, self-renewal and differentiation of hematopoietic stem cells.Hum Immunol. 2020 May;81(5):206-217. doi: 10.1016/j.humimm.2020.01.004. Epub 2020 Mar 2. Hum Immunol. 2020. PMID: 32139091 Review.
-
Hematopoietic stem cell expansion: challenges and opportunities.Ann N Y Acad Sci. 2012 Aug;1266:138-50. doi: 10.1111/j.1749-6632.2012.06549.x. Ann N Y Acad Sci. 2012. PMID: 22901265 Review.
Cited by
-
Deciphering Age-Dependent ECM Remodelling in Liver: Proteomic Profiling and Its Implications for Aging and Therapeutic Targets.Cell Prolif. 2025 Sep;58(9):e70087. doi: 10.1111/cpr.70087. Epub 2025 Jun 19. Cell Prolif. 2025. PMID: 40537154 Free PMC article.
-
Characterization and structure-based protein engineering of a regiospecific saponin acetyltransferase from Astragalus membranaceus.Nat Commun. 2023 Sep 25;14(1):5969. doi: 10.1038/s41467-023-41599-7. Nat Commun. 2023. PMID: 37749089 Free PMC article.
-
Damage of the Bone Marrow Stromal Precursors in Patients with Acute Leukemia at the Onset of the Disease and During Treatment.Int J Mol Sci. 2024 Dec 11;25(24):13285. doi: 10.3390/ijms252413285. Int J Mol Sci. 2024. PMID: 39769050 Free PMC article.
-
The processed Sanguisorba officinalis L. triterpenoids prevent colon cancer through the TNF-α/NF-κB signaling pathway, combined with network pharmacology, molecular simulation dynamics and experimental verification.Front Immunol. 2025 Jun 18;16:1605326. doi: 10.3389/fimmu.2025.1605326. eCollection 2025. Front Immunol. 2025. PMID: 40607420 Free PMC article.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous
